PMVP Historical PE Ratio Notes

— PMV Pharmaceuticals (ticker: PMVP) is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines targeting the p53 pathway, which is implicated in over half of all cancers. Their most advanced product candidates are designed to reactivate mutant p53 protein, potentially restoring its tumor-suppressing function. This focus on innovative cancer therapeutics means PMVP has historically generated little or no revenue, as its programs are still in clinical trials and not yet commercialized. As a result, investors reviewing PMVP's historical price, earnings, and pe ratio ("price/earnings ratio") information will likely see negative or undefined pe ratios for most periods, since the company has reported losses rather than profits; the market often values such development-phase biotechs based on future expectations rather than current earnings. When reviewing PMVP's historical pe ratio charts, keep in mind that shifts in the ratio, if and when it becomes positive, are more likely triggered by major clinical or regulatory milestones, changes in investor sentiment regarding the company's drug pipeline, or broader biotech market conditions, rather than changes in actual operating earnings.

On this page we presented the PMV Pharma Historical PE Ratio information for PMV Pharma' stock. The average PMVP historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 2.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average PMVP historical PE based on this TTM earnings result method is 15.8. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this PMVP historical PE result, against the recent PE: when this page was posted on 6/25/2026, the most recent closing price for PMVP had been 1.15, and the most recent quarterly earnings result, annualized, was 14.12. Meanwhile, the most recent TTM earnings summed to 2.65. From these numbers, we calculate the recent PMVP PE on 6/25/2026 based on annualized quarterly EPS was 0.1. Based on PMVP's history, that recent PE is low relative to the historical average, with the recent PE 96.0% lower than the historical average PE across our data set for PMV Pharma. Looking at the recent PMVP PE on 6/25/2026 based on TTM EPS, we calculate the ratio at 0.4. Based on PMVP's history, that recent PE is low relative to the historical average, with the recent PE 97.5% lower than the average PE across our PMV Pharma data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on PMVP or any other given stock, valuation analysis for PMVP can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate PMV Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for PMVP. Thanks for visiting, and the next time you need to research PMVP Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.